CORT Corcept Therapeutics Incorporated
Company Analysis
Latest News
🟢 Corcept Therapeutics is trading 4.77% up in after-hours trading amid broad-market gains
Corcept Therapeutics is trading at $83.00, up 4.77%, amid broad-market gains; no company-specific catalyst for the November 4 after-hours rise was...
🔴 Corcept Therapeutics is trading 7% down today as unchanged 2026 guidance disappointed investors
Corcept Therapeutics is trading at $76.04 (-7.19%) after management reiterated 2026 revenue guidance of $1.1–$1.2 billion rather than raising it, a source of...
🟢 Corcept Therapeutics is trading 6.19% up in pre-market after Q3 revenue surged 64% year over year
Corcept Therapeutics is trading at $87.00, up 6.19% in pre-market after reporting third-quarter revenue of $340.5 million, up 64% year over year. - Lifyorli...
🔴 Corcept Therapeutics is trading 7% down in pre-market after investors focused on unchanged 2026 revenue guidance
Corcept Therapeutics is trading at $76.23 (-6.96%) as investors reacted to unchanged 2026 revenue guidance despite earnings and revenue beating...
🔴 Corcept Therapeutics is trading 8.46% down in after-hours trading after Q3 release with guidance reiterated
Corcept Therapeutics is trading at $75.00 (-8.46%) in after-hours trading following its Q3 earnings release; available sources do not establish which result...
Corcept Therapeutics third quarter revenue surged 64% as Lifyorli launch and Korlym sales beat estimates
Corcept Therapeutics reported third quarter 2026 results that significantly outperformed expectations, with total revenue of $340.5 million exceeding the...
🟢 Corcept Therapeutics is trading 4.03% up today amid broad biotech-sector gains
Corcept Therapeutics is trading $83.70, up 4.03%, with biotech-sector strength providing the immediate backdrop. - As of 1:45 p.m. ET on November 3, the XBI...
Corcept Surges 12% Before Earnings — Can a Cancer Drug and a Billion-Dollar Guidance Back Up the Optimism?
Shares of Corcept Therapeutics jumped 12.4% in pre-market trading to $91.17 on November 2, the day before the company is set to report third-quarter results....
🟢 Corcept Therapeutics is trading 12.39% up in pre-market ahead of November 3 Q3 results
Corcept Therapeutics is trading $91.17 (+12.39%) in pre-market amid anticipation of its November 3 Q3 results; no direct cause is confirmed. - The company...
Corcept Therapeutics Incorporated Q3 2026 Earnings Preview: What Analysts Expect on November 03, 2026
Corcept Therapeutics is expected to report Q3 2026 revenue of $215.42 million and EPS of $0.68, with the current stock price of $56.42 trading below the...
🔴 Corcept Therapeutics is trading 6.5% down; no verified company-specific explanation
Corcept Therapeutics is trading at $80.44, down 6.49%, with no verified company-specific announcement identified to explain the decline. - Corcept’s...
🟢 Corcept Therapeutics is trading 6.07% up in after-hours trading with no verified company-specific catalyst identified
Corcept Therapeutics is trading 6.07% up after hours at $91.17 on October 29, with no verified company-specific announcement explaining the rise. -...
🟢 Corcept Therapeutics is trading 5% up in after-hours trading
Corcept Therapeutics is trading at $91.02, up 5.49%, with no verified company-specific announcement explaining the October 28 after-hours move. - The latest...
🟢 Corcept Therapeutics is trading 4.64% up in pre-market after positive Phase 2 BELLA results
Corcept Therapeutics is trading at $91.17, up 4.64% in pre-market on October 27 after positive Phase 2 BELLA results announced October 26. - Among 95...
🟢 Corcept Therapeutics is trading 5% up today after BELLA trial showed 59% response rate
Corcept Therapeutics is trading 5.26% higher at $90.38 on October 26 after positive Phase 2 BELLA Part A results. - Among 95 patients with platinum-resistant...
🔴 Corcept Therapeutics is trading 10.9% down today with no new company-specific catalyst identified
Corcept Therapeutics is trading at $95.74, with a -10.94% change; no new catalyst was identified for October 23. - Available coverage reports no new macro,...
🔴 Corcept Therapeutics is trading 5.5% down today as Nasdaq and S&P 500 slide
Corcept Therapeutics is trading at $109.86, down 5.5%, with broad market weakness the likeliest explanation; a specific cause for the larger decline is...
Corcept Therapeutics Gains Support as ADA and EASD Recommend Hypercortisolism Screening
A new consensus report from the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) recommends screening patients...
🔴 Corcept Therapeutics is trading 4.25% down in pre-market
Corcept Therapeutics is trading at $111.50, down -4.25% before the October 21, 2026 session; no clear catalyst has been identified. - The price compares with...
🟢 Corcept Therapeutics is trading 4.17% up today amid biotech-sector gains
Corcept Therapeutics is trading at $116.77, up 4.17%, amid biotech-sector strength. - No clear company-specific announcement dated October 20, 2026, emerged...